Total Payments
$2.2M
2024 Payments
$207,604
Companies
75
Transactions
776
Medicare Patients
13,935
Medicare Billing
$232,600
Payment Breakdown by Category
Consulting$1.8M (84.3%)
Research$197,920 (9.1%)
Other$113,577 (5.2%)
Travel$22,679 (1.0%)
Food & Beverage$6,474 (0.3%)
Education$5.90 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $1.8M | 472 | 84.3% |
| Unspecified | $197,920 | 111 | 9.1% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $103,002 | 33 | 4.7% |
| Travel and Lodging | $22,679 | 58 | 1.0% |
| Honoraria | $7,200 | 1 | 0.3% |
| Food and Beverage | $6,474 | 96 | 0.3% |
| Grant | $3,375 | 4 | 0.2% |
| Education | $5.90 | 1 | 0.0% |
Payments by Type
General
$2.0M
665 transactions
Research
$197,920
108 transactions
Ownership
$0
3 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Janssen Research & Development, LLC | $240,025 | 69 | $0 (2024) |
| Braemar Manufacturing, LLC | $205,023 | 5 | $0 (2019) |
| UCB SA | $168,300 | 33 | $0 (2024) |
| GlaxoSmithKline, LLC. | $137,888 | 42 | $0 (2024) |
| SANOFI-AVENTIS U.S. LLC | $137,488 | 76 | $0 (2023) |
| ABBVIE INC. | $113,075 | 51 | $0 (2024) |
| E.R. Squibb & Sons, L.L.C. | $91,754 | 35 | $0 (2024) |
| Takeda Pharmaceuticals U.S.A., Inc. | $80,719 | 19 | $0 (2024) |
| AstraZeneca UK Limited | $76,402 | 49 | $0 (2024) |
| Novartis Pharma AG | $75,869 | 33 | $0 (2023) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $207,604 | 78 | E.R. Squibb & Sons, L.L.C. ($49,800) |
| 2023 | $196,374 | 64 | Janssen Research & Development, LLC ($37,150) |
| 2022 | $253,759 | 80 | UCB SA ($49,800) |
| 2021 | $246,405 | 75 | UCB SA ($43,200) |
| 2020 | $249,787 | 72 | Takeda Pharmaceuticals U.S.A., Inc. ($49,800) |
| 2019 | $326,238 | 118 | Braemar Manufacturing, LLC ($66,000) |
| 2018 | $315,716 | 138 | Braemar Manufacturing, LLC ($66,000) |
| 2017 | $380,357 | 151 | Braemar Manufacturing, LLC ($73,023) |
All Payment Transactions
776 individual payment records from CMS Open Payments — Page 1 of 32
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/23/2024 | Janssen Research & Development, LLC | — | Consulting Fee | Cash or cash equivalent | $3,100.00 | General |
| 12/19/2024 | E.R. Squibb & Sons, L.L.C. | Sotyktu (Drug) | Consulting Fee | Cash or cash equivalent | $7,800.00 | General |
| Category: Immunology | ||||||
| 12/13/2024 | UCB SA | Bimzelx (Biological) | Consulting Fee | Cash or cash equivalent | $1,500.00 | General |
| Category: Immunology | ||||||
| 12/13/2024 | UCB SA | Bimzelx (Biological) | Consulting Fee | Cash or cash equivalent | $1,500.00 | General |
| Category: Immunology | ||||||
| 11/27/2024 | GlaxoSmithKline, LLC. | — | Consulting Fee | Cash or cash equivalent | $9,600.00 | General |
| 11/11/2024 | Janssen Research & Development, LLC | — | Consulting Fee | Cash or cash equivalent | $1,200.00 | General |
| 11/07/2024 | AstraZeneca UK Limited | SAPHNELO (Biological) | Consulting Fee | Cash or cash equivalent | $600.00 | General |
| Category: Inflammation and Autoimmunity | ||||||
| 11/04/2024 | Takeda Pharmaceuticals U.S.A., Inc. | — | Consulting Fee | Cash or cash equivalent | $1,200.00 | General |
| 10/29/2024 | GlaxoSmithKline, LLC. | — | Consulting Fee | Cash or cash equivalent | $4,750.00 | General |
| 10/22/2024 | ABBVIE INC. | SKYRIZI (Biological) | Consulting Fee | Cash or cash equivalent | $1,300.00 | General |
| Category: IMMUNOLOGY | ||||||
| 10/01/2024 | Janssen Research & Development, LLC | — | Consulting Fee | Cash or cash equivalent | $6,820.00 | General |
| 09/25/2024 | E.R. Squibb & Sons, L.L.C. | — | Consulting Fee | Cash or cash equivalent | $12,000.00 | General |
| 09/23/2024 | GlaxoSmithKline, LLC. | — | Consulting Fee | Cash or cash equivalent | $1,500.00 | General |
| 09/18/2024 | Chiesi USA, Inc. | JUXTAPID (Drug) | — | Cash or cash equivalent | $300.00 | Research |
| Study: LOWER:LomitapideObservational Worldwide Evaluation Registry (LOWER) • Category: HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA | ||||||
| 09/12/2024 | AstraZeneca UK Limited | SAPHNELO (Biological) | Consulting Fee | Cash or cash equivalent | $2,700.00 | General |
| Category: Inflammation and Autoimmunity | ||||||
| 09/05/2024 | AstraZeneca UK Limited | SAPHNELO (Biological) | Consulting Fee | Cash or cash equivalent | $600.00 | General |
| Category: Inflammation and Autoimmunity | ||||||
| 09/03/2024 | ModernaTX, Inc. | — | Consulting Fee | Cash or cash equivalent | $3,250.00 | General |
| 09/03/2024 | ModernaTX, Inc. | — | Consulting Fee | Cash or cash equivalent | $1,300.00 | General |
| 09/03/2024 | ModernaTX, Inc. | — | Consulting Fee | Cash or cash equivalent | $975.00 | General |
| 09/03/2024 | ModernaTX, Inc. | — | Consulting Fee | Cash or cash equivalent | $650.00 | General |
| 09/03/2024 | ModernaTX, Inc. | — | Consulting Fee | Cash or cash equivalent | $325.00 | General |
| 08/29/2024 | ABBVIE INC. | — | Consulting Fee | Cash or cash equivalent | $1,950.00 | General |
| 08/15/2024 | E.R. Squibb & Sons, L.L.C. | — | — | Cash or cash equivalent | $2,700.00 | Research |
| Study: Long-Term Study That Measures the Safety and Efficacy of Deucravacitinib (BMS-986165) in Participants With Psoriasis (POETYK PSO-LTE) | ||||||
| 08/06/2024 | E.R. Squibb & Sons, L.L.C. | Sotyktu (Drug) | Consulting Fee | Cash or cash equivalent | $6,600.00 | General |
| Category: Immunology | ||||||
| 08/05/2024 | GlaxoSmithKline, LLC. | — | Consulting Fee | Cash or cash equivalent | $5,500.00 | General |
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 DOSE RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF 2 DOSE REGIMENS OF INTRAVENOUS TAK-954 FOR THE PROPHYLAXIS AND TREATMENT OF POSTOPERATIVE GASTROINTESTINAL DYSFUNCTION IN PATIENTS UNDERGOING LARGE- AND SMALL-BOWEL RESECTION | Takeda Pharmaceuticals U.S.A., Inc. | $52,200 | 7 |
| Long-Term Study That Measures the Safety and Efficacy of BMS-986165 in Participants With Psoriasis | E.R. Squibb & Sons, L.L.C. | $15,600 | 6 |
| CLEE011F2301 | Novartis Pharma AG | $15,376 | 6 |
| The purpose of this study is to characterise longterm safety and tolerability of intravenous anifrolumab A Multicentre Randomised Double blind Placebo Controlled Phase 3 Extension Study to Characterise the Long term Safety and Tolerability of Anifrolumab in Adult Subjects With Active Systemic Lupus Erythematosus | AstraZeneca UK Limited | $14,321 | 4 |
| A STUDY OF TAK-105 IN HEALTHY ADULTS | Takeda Pharmaceuticals U.S.A., Inc. | $10,500 | 3 |
| LOWER: Lomitapide Observational Worldwide Evaluation Registry | Amryt Pharma Holdings Ltd | $9,375 | 12 |
| MYL-1701P | Mylan Inc. | $8,700 | 3 |
| A Multi-Center, Randomized, Double-Blind, Placebo- and Active Comparator-Controlled Phase 3 Study with an Induction Period Followed by a Randomized Maintenance Period to Evaluate the Clinical Efficacy and Safety of BMS-986165 in Subjects with Mod | E.R. Squibb & Sons, L.L.C. | $6,150 | 2 |
| A Multi-Center, Randomized, Double-Blind, Placebo- and Active Comparator-Controlled Phase 3 Study to Evaluate the Clinical Efficacy and Safety of BMS-986165 in Subjects with Moderate to Severe Psoriasis | E.R. Squibb & Sons, L.L.C. | $6,000 | 3 |
| EURopean trial in atrial fibrillation or flutter patientss receiving DRO for the maIntenance of sinus rhythm | SANOFI-AVENTIS U.S. LLC | $5,289 | 9 |
| A Phase 1, Adaptive, Open-Label, Single Ascending Dose to Single-Blind, Placebo-Controlled, Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of mRNA-0184 in Participants with Chronic Heart Failure | ModernaTX, Inc. | $4,225 | 1 |
| A placebo-controlled, double-blind, parallel arm Trial to asses the efficacy of DRO 400 mg bid for the prevention of cardiovascular Hospitalization | SANOFI-AVENTIS U.S. LLC | $4,191 | 7 |
| CLEE011G2301 | Novartis Pharma AG | $3,750 | 2 |
| The purpose of this study is to evaluate the efficacy and safety of an intravenous treatment regimen of anifrolumab versus placebo in adult subjects with moderately to severely active autoantibody positive systemic lupus erythematosus SLE | AstraZeneca UK Limited | $3,500 | 2 |
| The purpose of this study is to evaluate the efficacy and safety of an intravenous treatment regimen of two doses of anifrolumab versus placebo in adult subjects with moderately to severely active autoantibody positive systemic lupus erythematosus SLE | AstraZeneca UK Limited | $3,500 | 2 |
| A Multi-Center, Randomized, Double-Blind, Placebo- and Active Comparator-Controlled Phase 3 Study with an Induction Period Followed by a Randomized Maintenance Period to Evaluate the Clinical Efficacy and Safety of BMS-986165 in Subjects with Moderate to | E.R. Squibb & Sons, L.L.C. | $3,300 | 2 |
| A Phase 2 Study to Investigate the Safety and Efficacy of Elsubrutinib and Upadacitinib Given Alone or in Combination (ABBV-599 Combination) in Subjects with Moderately to Severely Active Systemic Lupus Erythematosus | ABBVIE INC. | $3,000 | 3 |
| A RANDOMIZED, DOUBLE-BLIND, SPONSOR-OPEN, PLACEBO-CONTROLLED, PHASE 1 STUDY TO EVALUATE THE SAFETY, TOLERABILITY, AND PHARMACOKINETICS OF TAK-105 IN HEALTHY SUBJECTS | Takeda Pharmaceuticals U.S.A., Inc. | $3,000 | 1 |
| Long-Term Study That Measures the Safety and Efficacy of Deucravacitinib (BMS-986165) in Participants With Psoriasis (POETYK PSO-LTE) | E.R. Squibb & Sons, L.L.C. | $2,700 | 1 |
| EURopean Trial In Atrial Fibrillation or Flutter Patients Receiving Dronedarone for the maIntenance of Sinus Rhythm (EURIDIS) | SANOFI-AVENTIS U.S. LLC | $2,500 | 2 |
| Phase III PsA - A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Deucravacitinib in Participants with Active Psoriatic Arthritis who are Na ve to Biologic Disease-modifying Anti-rheumatic Drugs. | E.R. Squibb & Sons, L.L.C. | $2,400 | 1 |
| A Study to Characterize the Pharmacokinetics, Pharmacodynamics, and Safety of Anifrolumab in Adult Type I Interferon Test High Systemic Lupus Erythematosus Subject With Active Skin Manifestations | AstraZeneca UK Limited | $2,000 | 2 |
| Safety and Efficacy of Two Doses of Anifrolumab Compared to Placebo in Adult Subjects With Active Proliferative Lupus Nephritis | AstraZeneca UK Limited | $1,897 | 4 |
| LOWER:LomitapideObservational Worldwide Evaluation Registry (LOWER) | Chiesi USA, Inc. | $1,500 | 3 |
| Aegerion Lomitapide ClinDevOps | Aegerion Pharmaceuticals, Inc. | $1,375 | 4 |
| A Randomized, Placebo-Controlled, Double-blind, Multicenter Study to Assess the Efficacy and Safety of Multiple Doses of BMS-986165 in Subjects With Active Psoriatic Arthritis (PsA) | E.R. Squibb & Sons, L.L.C. | $1,350 | 1 |
| This is a multiple dose randomised parallel double blind double dummy multicentre and multinational Phase III study to determine the efficacy and safety of Aclidinium bromide Formoterol fumarate compared with individual components and placebo and Aclidinium bromide compared with Placebo when administered to patients with stable Chronic Obstructive Pulmonary Disease COPD | AstraZeneca UK Limited | $1,250 | 1 |
| RANDOMIZED STUDY WITH COMPOSITE ENDPOINT | Hoffmann-La Roche Limited | $1,020 | 1 |
| Impact of Dronedarone on CV Hospitalization and Ventricular Proarrhythmia in AF Patients based on the Optum Clinformatics Data Mart, IBM MarketScan, Veterans Health Administration Electronic Health Records, and Swedish National Patient Register Databases Representative of the Entire Insured US and Swedish populations | SANOFI-AVENTIS U.S. LLC | $1,000 | 2 |
| A Study to Investigate the Safety and Efficacy of Elsubrutinib and Upadacitinib Given Alone or in Combination in Participants With Moderately to Severely Active Systemic Lupus Erythematosus (SLE) | ABBVIE INC. | $975.00 | 1 |
| A Phase 1, Randomized, Double Blind, Placebo and Active Controlled, Parallel Study to Evaluate the Effect of Repeat Doses of Isavuconazole on Cardiac Repolarization in Healthy Adult Subjects | Astellas Pharma Global Development | $944.58 | 1 |
| Reveal AF | Medtronic Vascular, Inc. | $937.50 | 2 |
| EURopean Trial In Atrial Fibrillation(AF) or Flutter (AFL) Patients Receiving Dronedarone for the maIntenance of Sinus Rhythm (EURIDIS) (EURIDIS),American-Australian-African Trial With Dronedarone in | SANOFI-AVENTIS U.S. LLC | $730.91 | 1 |
| M19-130 | AbbVie Inc. | $600.00 | 2 |
| Lomitapide Peri & Post | Aegerion Pharmaceuticals, Inc. | $375.00 | 1 |
| An Investigational Study to Evaluate Experimental Medication BMS-986165 Compared to Placebo in Participants With Plaque Psoriasis (POETYK-PSO-3) in Mainland China, Taiwan, and South Korea (POETYK-PSO-3) | E.R. Squibb & Sons, L.L.C. | $300.00 | 1 |
| EURopean Trial In Atrial Fibrillation(AF) or Flutter (AFL) Patients Receiving Dronedarone for the maIntenance of Sinus Rhythm (EURIDIS) (EURIDIS) | SANOFI-AVENTIS U.S. LLC | $289.09 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 3 | 3,189 | 4,933 | $179,895 | $42,338 |
| 2022 | 5 | 3,217 | 4,910 | $210,255 | $58,892 |
| 2021 | 6 | 3,583 | 5,642 | $231,415 | $65,394 |
| 2020 | 8 | 3,946 | 6,498 | $249,554 | $65,977 |
Total Patients
13,935
Total Services
21,983
Medicare Billing
$232,600
Procedure Codes
22
All Medicare Procedures & Services
22 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 93010 | Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | Facility | 2023 | 2,849 | 4,528 | $135,840 | $28,314 | 20.8% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 168 | 197 | $30,535 | $11,929 | 39.1% |
| 93000 | Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | Office | 2023 | 172 | 208 | $13,520 | $2,095 | 15.5% |
| 93010 | Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | Facility | 2022 | 2,750 | 4,163 | $124,890 | $27,103 | 21.7% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 211 | 341 | $52,855 | $24,001 | 45.4% |
| 93000 | Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | Office | 2022 | 221 | 370 | $24,050 | $4,225 | 17.6% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 18 | 19 | $4,465 | $2,039 | 45.7% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2022 | 17 | 17 | $3,995 | $1,524 | 38.1% |
| 93010 | Routine electrocardiogram (ekg) using at least 12 leads with interpretation and report | Facility | 2021 | 3,086 | 4,884 | $146,520 | $33,146 | 22.6% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 207 | 328 | $50,035 | $23,728 | 47.4% |
| 93000 | Routine ekg using at least 12 leads including interpretation and report | Office | 2021 | 224 | 361 | $23,465 | $4,301 | 18.3% |
| 99442 | Physician telephone patient service, 11-20 minutes of medical discussion | Office | 2021 | 32 | 35 | $5,250 | $1,954 | 37.2% |
| 99203 | New patient outpatient visit, total time 30-44 minutes | Office | 2021 | 23 | 23 | $5,180 | $1,872 | 36.1% |
| 99212 | Established patient outpatient visit, total time 10-19 minutes | Office | 2021 | 11 | 11 | $965.00 | $392.32 | 40.7% |
| 93010 | Routine electrocardiogram (ekg) using at least 12 leads with interpretation and report | Facility | 2020 | 3,448 | 5,898 | $176,940 | $41,103 | 23.2% |
| 99442 | Physician telephone patient service, 11-20 minutes of medical discussion | Office | 2020 | 123 | 161 | $24,150 | $9,877 | 40.9% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Office | 2020 | 159 | 185 | $27,750 | $9,576 | 34.5% |
| 93000 | Routine ekg using at least 12 leads including interpretation and report | Office | 2020 | 166 | 201 | $13,065 | $2,490 | 19.1% |
| 99443 | Physician telephone patient service, 21-30 minutes of medical discussion | Office | 2020 | 11 | 12 | $2,700 | $1,087 | 40.3% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 11 | 11 | $2,399 | $1,015 | 42.3% |
| 99441 | Physician telephone patient service, 5-10 minutes of medical discussion | Office | 2020 | 14 | 14 | $1,190 | $438.15 | 36.8% |
| 99212 | Established patient office or other outpatient visit, typically 10 minutes | Office | 2020 | 14 | 16 | $1,360 | $390.70 | 28.7% |
About Dr. Peter Kowey, MD
Dr. Peter Kowey, MD is a Clinical Cardiac Electrophysiology healthcare provider based in Wynnewood, Pennsylvania. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 06/17/2005. The National Provider Identifier (NPI) number assigned to this provider is 1114922945.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Peter Kowey, MD has received a total of $2.2M in payments from pharmaceutical and medical device companies, with $207,604 received in 2024. These payments were reported across 776 transactions from 75 companies. The most common payment nature is "Consulting Fee" ($1.8M).
As a Medicare-enrolled provider, Kowey has provided services to 13,935 Medicare beneficiaries, totaling 21,983 services with total Medicare billing of $232,600. Data is available for 4 years (2020–2023), covering 22 distinct procedure/service records.
Ad
Practice Information
- Specialty Clinical Cardiac Electrophysiology
- Other Specialties Cardiovascular Disease
- Location Wynnewood, PA
- Active Since 06/17/2005
- Last Updated 06/17/2016
- Taxonomy Code 207RC0001X
- Entity Type Individual
- NPI Number 1114922945
Products in Payments
- Cardiac Monitoring Suite (Device) $205,023
- Movantik (Drug) $56,443
- MULTAQ (Drug) $51,268
- OFEV (Drug) $37,850
- Sotyktu (Drug) $35,100
- LAQUINIMOD (Drug) $32,400
- LCZ696_ENTRESTO_CARDIOVASCULAR (Drug) $26,202
- LEMTRADA (Drug) $24,270
- CIALIS (Drug) $23,700
- Vascepa (Drug) $23,677
- Lucemyra/Lofexidine (Drug) $23,544
- DUPIXENT (Drug) $22,946
- NO PRODUCT DISCUSSED (Drug) $21,825
- MOVANTIK (Drug) $21,668
- CAM2038 $18,401
- ENTRESTO (Drug) $18,235
- SKYRIZI (Biological) $17,225
- Bimzelx (Biological) $16,800
- SAPHNELO (Biological) $16,250
- LEE011F (Drug) $14,384
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Clinical Cardiac Electrophysiology Doctors in Wynnewood
Steven Rothman, Md, MD
Clinical Cardiac Electrophysiology — Payments: $123,681
Clinical Cardiac Electrophysiology $123,681
Douglas Esberg, Md, MD
Clinical Cardiac Electrophysiology — Payments: $79,456
Clinical Cardiac Electrophysiology $79,456
Ali Keramati, M.d, M.D
Clinical Cardiac Electrophysiology — Payments: $67,736
Clinical Cardiac Electrophysiology $67,736
Kar Lai Wong, M.d, M.D
Clinical Cardiac Electrophysiology — Payments: $8,991
Clinical Cardiac Electrophysiology $8,991
Gan Xin Yan, Md, MD
Clinical Cardiac Electrophysiology — Payments: $7,444
Clinical Cardiac Electrophysiology $7,444
Maribel Hernandez, Md, MD
Clinical Cardiac Electrophysiology — Payments: $6,571
Clinical Cardiac Electrophysiology $6,571